ResearchNurses.co, a UK-based research nurses provider, has been awarded a contract with Nottingham University Hospitals Research and Innovation Department to provide research nursing services for clinical trials related to multiple sclerosis (MS).
As part of the project, research nurses will work alongside three major pharmaceutical sponsors as well as the MS Society in clinical trials for patients with relapsing-remitting MS and secondary progressive MS.
ResearchNurses.co will be working with some of the country’s leading neurologist consultants and investigators at the hospital including Professor Chris Constantinescu, Dr Bruno Gran and Dr Nikos Evangelou.
Dr Maria Koufali, Deputy Director for Research & Innovation at Nottingham University Hospitals said: “These studies are of huge importance to everyone affected by multiple sclerosis and we are keen to offer them to as many patients as possible. This will ensure patient access to innovative medicines but also improvement of our MS clinical services.
“ResearchNurses.co have been extremely quick and efficient at responding to our needs and have demonstrated that they are able to provide a wide-ranging and reliable service, helping us to ensure the integrity of our trial data as well as ensuring trial participants are comfortable throughout the study.”
Based at Nottingham’s Queens Medical Center, ResearchNurses.co will liaise with key sponsors and investigators to oversee and provide drug infusions and venepuncture, as well as providing processing and monitoring services.
John Illingworth, managing director of ResearchNurses.co added: “Many of our clients require nursing assistance and on-site support, our research nurses have extensive experience in fitting into existing team structures as well as expert knowledge of key protocols allowing them to provide a tailor made service and additional resource where it matters most.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.